Nontuberculous Mycobacterial Infections - Pipeline Insight, 2024

Nontuberculous Mycobacterial Infections - Pipeline Insight, 2024

DelveInsight’s, “Nontuberculous Mycobacteria (NTM) Infections - Pipeline Insight, 2024,” report provides comprehensive insights about 14+ companies and 14+ pipeline drugs in Nontuberculous Mycobacteria (NTM) Infections pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Nontuberculous Mycobacteria (NTM) Infections Understanding

Nontuberculous Mycobacteria (NTM) Infections: Overview

Non-tuberculous mycobacteria (NTM) are ubiquitous, free living, environmental saprophytic organisms known to occupy water systems, soil, and vegetation. Infections caused by NTM is known as Nontuberculous Mycobacteria (NTM) Infections. NTM disease presents a wide variety of clinical syndromes, from lymphadenopathy (commonly cervical lymph nodes) to aseptic meningitis. Diagnosis of nontuberculous mycobacterial (NTM) lung disease include chest radiograph, three or more sputum specimens for acid-fast bacilli (AFB) analysis and exclusion of other disorders, such as tuberculosis (TB). Clinical, radiographic, and microbiologic criteria are equally important and all must be met to make a diagnosis of NTM lung disease. Treatment for NTM infections generally prolonged (12–18 months) multi-drug therapy. Disease remission rates vary depending on infecting species, patient age and comorbidities.

""Nontuberculous Mycobacteria (NTM) Infections - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Nontuberculous Mycobacteria (NTM) Infections pipeline landscape is provided which includes the disease overview and Nontuberculous Mycobacteria (NTM) Infections treatment guidelines. The assessment part of the report embraces, in depth Nontuberculous Mycobacteria (NTM) Infections commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Nontuberculous Mycobacteria (NTM) Infections collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Nontuberculous Mycobacteria (NTM) Infections R&D. The therapies under development are focused on novel approaches to treat/improve Nontuberculous Mycobacteria (NTM) Infections.

Nontuberculous Mycobacteria (NTM) Infections Emerging Drugs Chapters

This segment of the Nontuberculous Mycobacteria (NTM) Infections report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Nontuberculous Mycobacteria (NTM) Infections Emerging Drugs

• RHB 204: RedHill Biopharma

RHB-204 is a proprietary, fixed-dose oral capsule containing a combination of clarithromycin, rifabutin, and clofazimine. The drug is in Phase III development for the treatment of pulmonary nontuberculous mycobacteria (NTM) infections caused by Mycobacterium avium Complex (MAC). RHB-204 was granted both FDA Orphan Drug Designation for the treatment of NTM disease and QIDP Designation under the Generating Antibiotic Incentives Now Act (GAIN Act).

• MAT2501: Matinas BioPharma

MAT2501 is an orally-administered Lipid Nano-Crystal formulation of the gram-negative antibiotic agent, amikacin. The drug is in Phase I clinical development for the treatment of Nontuberculous Mycobacteria (NTM) Infections. As a broad-spectrum aminoglycoside, amikacin is highly effective in treating a range of chronic and acute bacterial infections, including Non-Tuberculous Mycobacterium (NTM) infections. FDA designated MAT2501 as a QIDP and Orphan Drug for the treatment of NTM infections.

Further product details are provided in the report……..

Nontuberculous Mycobacteria (NTM) Infections: Therapeutic Assessment

This segment of the report provides insights about the different Nontuberculous Mycobacteria (NTM) Infections drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Nontuberculous Mycobacteria (NTM) Infections

There are approx. 14+ key companies which are developing the therapies for Nontuberculous Mycobacteria (NTM) Infections. The companies which have their Nontuberculous Mycobacteria (NTM) Infections drug candidates in the most advanced stage, i.e. Phase III include, RedHill Biopharma.

• Phases

DelveInsight’s report covers around 14+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Nontuberculous Mycobacteria (NTM) Infections pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Nontuberculous Mycobacteria (NTM) Infections: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Nontuberculous Mycobacteria (NTM) Infections therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Nontuberculous Mycobacteria (NTM) Infections drugs.

Nontuberculous Mycobacteria (NTM) Infections Report Insights

• Nontuberculous Mycobacteria (NTM) Infections Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Nontuberculous Mycobacteria (NTM) Infections Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Nontuberculous Mycobacteria (NTM) Infections drugs?
• How many Nontuberculous Mycobacteria (NTM) Infections drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Nontuberculous Mycobacteria (NTM) Infections?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Nontuberculous Mycobacteria (NTM) Infections therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Nontuberculous Mycobacteria (NTM) Infections and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• RedHill Biopharma
• Janssen Pharmaceutical
• Spero Therapeutics
• Revimmune
• Matinas BioPharma
• MannKind Corporation
• Spero Therapeutics
• Shionogi
• Crestone

Key Products

• RHB 204
• Bedaquiline
• SPR 720
• CYT107
• MAT2501
• MNKD-10
• SPR-719
• Research programme: mycobacterial disease therapeutics
• MmpL3 inhibitor